Funds with heavy exposure to financials are at the bottom of the IMA China sector over six months, as China's banking reforms caused a savage sell-off in financial stocks.
Wealth managers have revealed five lesser-known funds they are backing to outperform peers this year, in an environment where some major equity and bond markets looked stretched.
Former AXA Framlington Biotechnology fund manager Andy Smith has joined biopharma specialist Mann Bioinvest to launch an income-focused fund in the coming weeks.